Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer

Cancer

Volumn 115, Issue 8, 2009, Pages 1701-1712

  De Pau, Enrique Carrillo Santa ^b   Arias, Fernando Carrillo ^c   Peláez, Enrique Caso ^d   Molina, Gemma Maria Muñoz ^b   Hernandez, Ignacio Sánchez ^c   Trueba, Ignacio Muguruza ^b   Balsalobre, Ramón Moreno ^e   Sacristánlopez, Silvia ^b   Pinillos, Alejandro Gómez ^b   Del Val Toledo Lobo, María ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Guadalajara Hospital   (Spain)

^d UNIVERSITY OF VIGO   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Angiogenesis inducing agents; Lung neoplasms; Survival analysis; Vascular endothelial growth factor; Vascular endothelial growth factor receptors

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 65249090875     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24193     Document Type: Article

References (62)

1. World Health Organization. World Health Statistics 2006. Geneva, Switzerland: World Health Organization; 2006. Available at: http://www.who.int/ whosis/whostat2006/en/ index.html Accessed December 1, 2007.
2. Halmos B, Boiselle PM, Karp DD. Lung cancer. Prim Care Update Ob Gyns. 2003;10:87-94.
3. Travis WD. Pathology of lung cancer. Clin Chest Med. 2002;23:65-81.
4. Sant M, Aareleid T, Berrino F. EUROCARE-3: survival of cancer patients diagnosed 1990-1994. Results and commentary. Ann Oncol. 2003;14(suppl. 5):v61-v118.
5. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599 [abstract]. J Clin Oncol. 2005;23 (suppl. 1):16S. Abstract 4.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
7. Poon RT, Fan S, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207-1225.
8. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853-865.
9. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 2006;580:2879-2887.
10. Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 1998;153:103-108.
11. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198.
12. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothe- lial growth factor-C mediated lymphangiogenesis promotes tumor metastasis. EMBO J. 2001;20:672-682.
13. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186-191.
14. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squa- mous cell lung cancer. Int JCancer. 1997;74:64-68.
15. Decaussin M, Sartelet H, Robert C, et al. Expression of vascular endothelial growth factor (VEGF) and its 2 receptors (VEGF-R1-Flt1 and VEGF-R2-FM/KDR) in non- small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. JPathol. 1999;188:369-377.
16. Seto T, Higashiyama M, Funai H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small cell lung cancer. Lung Cancer. 2006;53:91-96.
17. Takenaka K, Katakura H, Chen F, et al. The ratio of membrane-bound form Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer. Cancer Lett. 2007;246(1-2):34-40.
18. Liu B, Earl HM, Baban D, et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun. 1995;217:721-727.
19. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2005;174:215-222.
20. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001;98:1904-1913.
21. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468-475.
22. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-958.
23. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer. 1996;73:931-934.
24. Mattern J, Koomagi R, Volm M. Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density. Anticancer Res. 1997;17:2249-2252.
25. Delmotte P, Martin B, Paesmans M, et al. VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis. Rev Mal Respir. 2002;19:577-584.
26. Yano T, Tanikawa S, Fujie T, et al. Vascular endothelial growth factor expression and neovascularisation in non- small cell lung cancer. Eur J Cancer. 2000;36:601-609.
27. Toomey D, Smyth G, Condron C, et al. Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma. Cancer. 2001;92:2648-2657.
28. Liao M, Wang H, Lin Z, et al. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 2001;33:125-132.
29. Baillie R, Carlile J, Pendleton N, Schor AM. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol. 2001;54:116-120.
30. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer. 2005;49:325-335.
31. Kajita T, Ohta Y, Kimura K, et al. The expression of vascular endothelial growth factor C and its receptors in non- small cell lung cancer. Br J Cancer. 2001;85:255-260.
32. Arinaga M, Noguchi T, Takeno S, et al. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with non- small cell lung carcinoma. Cancer. 2003;97:457-464.
33. Ogawa E, Takenaka K, Yanagihara K, et al. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer. 2004;91:498-503.
34. Kojima H, Shijubo N, Yamada G, et al. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104:1668-1677.
35. Chen F, Takenaka K, Ogawa E, et al. Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer. Clin Cancer Res. 2004;10:8548-8553.
36. Juttner S, Wissmann C, Jons T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: 2 novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24:228-240.
37. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin Cancer Res. 2003;9:716-721.
38. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-D expression, nodal status, and prognosis in breast cancer. Clin Cancer Res. 2003;9:5313-5317.
39. Dales JP, Garcia S, Carpentier S, et al. Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n = 905). Br J Cancer. 2004;90:1216-1221.
40. Meunier-Carpentier S, Dales JP, Djemli A, et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR- 2 and Tie2 receptor expression in breast carcinoma. Int J Oncol. 2005;26:977-984.
41. Zhukova LG, Zhukov NV, Lichinitser MR. Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer. Bull Exp Biol Med. 2003;135:478-481.
42. World Health Organization. International Histological Classification of Tumours, 2nd ed. Berlin, Germany: Springer-Verlag; 1988.
43. Greene FL, Page DL, Fleming ID, et al, eds. American Joint Committee on Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
44. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxi- dase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
45. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994;173:371-379.
46. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203-212.
47. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and - 2. Curr Top Microbiol Immunol. 1999;237:59-83.
48. De Jong JS, Van Diest PJ, Van der Valk P, Baak J. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol. 1998;184:44-52.
49. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 2003;104:603-610.
50. Van Trappen PO, Steele D, Lowe DG, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF- D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol. 2003;201:544-554.
51. Maekawa S, Iwasaki A, Shirakusa T, et al. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res. 2007;27(6A):3735-3741.
52. Niki T, Iba S, Tokunou M, et al. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res. 2000;6:2431-2439.
53. Shida A, Fujioka S, Kobayashi K, et al. Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol. 2006;11:38-43.
54. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 2003;88:237-244.
55. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Expression of vascular endothelial growth factor (VEGF)- D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res. 2003;9:1361-1369.
56. Ishii H, Yazawa T, Sato H, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 2004;45:325-337.
57. Drescher D, Moehler M, Gockel I, et al. Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy? World J Gastroenterol. 2007;13:3605-3609.
58. Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathologi- cal and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol. 2007;33:294-300.
59. Sartelet H, Decaussin M, Devouassoux G, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 [Flt-1] and VEGF-R2 [KDR/Flk-1]) in tumorlets and in neuroendocrine cell hyperplasia of the lung. Hum Pathol. 2004;35:1210-1217.
60. Takizawa H, Kondo K, Fujino H, et al. The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br J Cancer. 2006;95:75-79.
61. Hiroshima K, Iyoda A, Shibuya K, et al. Evidence of neo- angiogenesis and increase in the number of proliferating cells within the bronchial epithelium of smokers. Cancer. 2002;95:1539-1545.
62. Lee JJ, Liu D, Lee JS, et al. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst. 2001;93:1081-1088.